Prostaglandin J2
Based on 1 Customer Validation
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with Kis of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC50 value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD).
For research use only. We do not sell to patients.
- Purity: 98.1%
- CAS No.: 60203-57-8
- Formula: C20H30O4
- Molecular Weight:334.45
-
Storage:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Endogenous Metabolite Isoforms
More
Biological Activity
|
hDP 0.9 nM (Ki) |
hCRTH2 6.6 nM (Ki) |
hEP1 15.678 μM (Ki) |
hEP2 989 nM (Ki) |
hEP3 319 nM (Ki) |
hEP4 1065 nM (Ki) |
hFP 553 nM (Ki) |
hIP >25 μM (Ki) |
hTP 6426 nM (Ki) |
Human Endogenous Metabolite |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sixteen-week-old Sprague Dawley male rats[4]
-
Dosage:33.4 μg/injection
-
Administration:Unilateral (right side) injections to the SNpc; once per week for 2 or 4 weeks
-
Result:Induced progressive dopaminergic neuronal loss in the rat substantia nigra pars compacta (SNpc).
Developed parkinsonian-like motor deficits in a progressive manner.
Chemical Information
-
CAS No. 60203-57-8
-
Appearance Liquid
-
Molecular Weight 334.45
-
Formula C20H30O4
-
Color Colorless to light yellow
-
SMILES
CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C=CC1=O)C/C=C\CCCC(O)=O
-
Synonyms
PGJ2
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Solution, -20°C, 2 years
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. D H Wright, et al. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24. [Content Brief]
[2]. Nicole Sawyer, et al. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72. [Content Brief]
[3]. Maria E Figueiredo-Pereira, et al. Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration. Ann N Y Acad Sci. 2016 Jan;1363(1):125-37. [Content Brief]
[4]. Chuhyon Corwin, et al. Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets. J Neuroinflammation. 2018 Sep 20;15(1):272. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Prostaglandin J2 Related Classifications
HY-113366 Related Classifications
Powered by Bioz
- Prostaglandin J2
- 60203-57-8
- PGJ2
- Prostaglandin J 2
- Prostaglandin J-2
- PGJ 2
- PGJ-2
- Prostaglandin Receptor
- Endogenous Metabolite
- endogenous metabolite
- prostaglandin D2
- PGD2
- DP
- Hdp
- hCRTH2
- cyclic AMP
- oxidative stress
- neuronal apoptosis
- ubiquitinated
- neurodegenerative
- Alzheimer's
- AD
- Parkinson's diseases
- PD
- Inhibitor
- inhibitor
- inhibit